JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glover, J. M.
Right arrow Articles by Shanahan, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glover, J. M.
Right arrow Articles by Shanahan, W. R., Jr.

Vol. 282, Issue 3, 1173-1180, 1997

Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302)1

Josephine M. Glover, Janet M. Leeds, Timothy G. K. Mant, Dipti Amin, Daniel L. Kisner, Joan E. Zuckerman, Richard S. Geary, Arthur A. Levin and William R. Shanahan, Jr.

Isis Pharmaceuticals Inc., Carlsbad, California (J.M.G., J.M.L., D.L.K., J.E.Z., R.S.G., A.A.L., W.R.S.) and Guy's Drug Research Unit Ltd, London SE1 1YR, United Kingdom (T.G.K.M., D.A.)

Healthy male volunteers received single or multiple intravenous infusions of an intercellular adhesion molecule-1 antisense phosphorothioate oligodeoxynucleotide, ISIS 2302, in a rising-dose (0.06-2.00 mg/kg infused over 2 hr), double-blind, placebo-controlled trial. Brief, dose-related increases in activated partial thromboplastin time were seen at the time of peak plasma concentration (Cmax). Clinically insignificant increases in C3a were seen after higher, repeated doses, but C5a, blood pressure and pulse were unaffected. No adverse events or other laboratory abnormalities were related to treatment with the drug. ISIS 2302 Cmax was linearly related to dose and occurred at the end of infusion. Plasma half-life for intact drug (53-54 min) and total oligonucleotide (67-74 min) were similar at the two doses (0.5 and 2.0 mg/kg) at which extensive pharmacokinetic data were collected. Nonlinear changes in area under the plasma concentration/time curve and steady-state volume of distribution with increasing dose suggested a saturable component to disposition. Metabolites co-migrating with n-1, n-2 and n-3 chain-shortened versions of ISIS 2302 appeared very rapidly in plasma, and disposition and metabolism appeared unaltered by repeated dosing. ISIS 2302 was well tolerated and behaved reproducibly with respect to plasma pharmacokinetics and expected side effects.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin
PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES
Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Sewell, R. S. Geary, B. F. Baker, J. M. Glover, T. G. K. Mant, R. Z. Yu, J. A. Tami, and F. A. Dorr
Phase I Trial of ISIS 104838, a 2'-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-alpha
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1334 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
E Rijcken, C F Krieglstein, C Anthoni, M G Laukoetter, R Mennigen, H U Spiegel, N Senninger, C F Bennett, and G Schuermann
ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease
Gut, October 1, 2002; 51(4): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
B R Yacyshyn, W Y Chey, J Goff, B Salzberg, R Baerg, A L Buchman, J Tami, R Yu, E Gibiansky, and W R Shanahan
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
Gut, July 1, 2002; 51(1): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
S. P. Henry, D.K. Monteith, J.E. Matson, B.H. Mathison, K.S. Loveday, R.A. Winegar, J.E. Matson, P.S. Lee, E.S. Riccio, J.P. Bakke, et al.
Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide
Mutagenesis, May 1, 2002; 17(3): 201 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher
A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Rudin, J. Holmlund, G. F. Fleming, S. Mani, W. M. Stadler, P. Schumm, B. P. Monia, J. F. Johnston, R. Geary, R. Z. Yu, et al.
Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1214 - 1220.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Z. Yu, H. Zhang, R. S. Geary, M. Graham, L. Masarjian, K. Lemonidis, R. Crooke, N. M. Dean, and A. A. Levin
Pharmacokinetics and Pharmacodynamics of an Antisense Phosphorothioate Oligonucleotide Targeting Fas mRNA in Mice
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 388 - 395.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin
Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
B. H. Dvorchik and J. K. Marquis
Disposition and Toxicity of a Mixed Backbone Antisense Oligonucleotide, Targeted against Human Cytomegalovirus, after Intravitreal Injection of Escalating Single Doses in the Rabbit
Drug Metab. Dispos., October 1, 2000; 28(10): 1255 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Waters, A. Webb, D. Cunningham, P. A. Clarke, F. Raynaud, F. di Stefano, and F. E. Cotter
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 9, 2000; 18(9): 1812 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. X. Chen, J. L. Marshall, E. Ness, R. R. Martin, B. Dvorchik, N. Rizvi, J. Marquis, M. McKinlay, W. Dahut, and M. J. Hawkins
A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors
Clin. Cancer Res., April 1, 2000; 6(4): 1259 - 1266.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. J. O'Dwyer, J. P. Stevenson, M. Gallagher, A. Cassella, I. Vasilevskaya, B. P. Monia, J. Holmlund, F. A. Dorr, and K.-S. Yao
c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)
Clin. Cancer Res., December 1, 1999; 5(12): 3977 - 3982.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Nemunaitis, J. T. Holmlund, M. Kraynak, D. Richards, J. Bruce, N. Ognoskie, T. J. Kwoh, R. Geary, A. Dorr, D. Von Hoff, et al.
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
J. Clin. Oncol., November 1, 1999; 17(11): 3586 - 3595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Stevenson, K.-S. Yao, M. Gallagher, D. Friedland, E. P. Mitchell, A. Cassella, B. Monia, T. J. Kwoh, R. Yu, J. Holmlund, et al.
Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)
J. Clin. Oncol., July 1, 1999; 17(7): 2227 - 2227.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
S. P. Henry, M. V. Templin, N. Gillett, J. Rojko, and A. A. Levin
Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1
Toxicol Pathol, January 1, 1999; 27(1): 95 - 100.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. M. Leeds, S. P. Henry, S. Bistner, S. Scherrill, K. Williams, and A. A. Levin
Pharmacokinetics of an Antisense Oligonucleotide Injected Intravitreally in Monkeys
Drug Metab. Dispos., July 1, 1998; 26(7): 670 - 675.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Graham, S. T. Crooke, D. K. Monteith, S. R. Cooper, K. M. Lemonidis, K. K. Stecker, M. J. Martin, and R. M. Crooke
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 447 - 458.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.